shares drug suspension
shares elan biogen idec plunged monday suspended multiple sclerosis drug tysabri patient death
york stock exchange shares elan lost partner biogen idec death central nervous system disease suspected condition cited involved tysabri avonex biogen idec existing multiple sclerosis drug reports rare condition progressive multifocal leukoencephalopathy pml patients tysabri avonex tysabri approved tipped leading multiple sclerosis treatment
clinical investigators evaluate patients consult leading experts understand risk pml outcome evaluations determine dosing clinical trials commercial availability
believed product provide opportunity biogen idec faced increased rivals avonex elan irish stock exchange receive boost product inquiry elan accounts brought close bankruptcy rebuilding increasing tysabri ian hunter goodbody stockbrokers dublin question mark elan finished biogen fell
shares pharmaceutical phytopharm closed pence stock exchange monday partner pull deal experimental alzheimer disease treatment phytopharm yamanouchi pharmaceutical licensing agreement prompting raise questions level reserves
